Pantoprazol Krka (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Krka, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Pantoprazol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Krka is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: heals erosions and reduces further damage. - Peptic ulcer disease: supports ulcer healing and prevents recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Helicobacter pylori eradication regimens (as adjunct): enhances ulcer healing when used with antibiotics.

Pantoprazol Krka may cause adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea: occasional mild upset. - Abdominal pain: mild cramping. - Flatulence: increased intestinal gas. - Constipation: occasional difficulty passing stool.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, breathing difficulty. - Clostridioides difficile infection: persistent watery diarrhoea. - Low magnesium (hypomagnesemia): muscle cramps, irregular heartbeat. - Liver enzyme elevation: asymptomatic rise in ALT/AST. - Bone fracture risk with long‑term use: especially in the elderly.

When prescribing Pantoprazol Krka, consider the following safety measures: - Assess renal and hepatic function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term users: evaluate need for continued therapy after 12 months. - Use cautiously in pregnancy: weigh benefits against potential risks. - Avoid in known hypersensitivity to pantoprazole or other PPIs. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazol Krka can affect the plasma concentrations of several co‑administered drugs. Interaction management is essential.

Major Interactions (Avoid): - Ketoconazole or itraconazole: markedly reduced antifungal absorption. - Atazanavir: significant loss of antiviral efficacy. - Clopidogrel: decreased antiplatelet activity.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Digoxin: modest rise in serum levels. - Methotrexate (high dose): reduced renal clearance, monitor toxicity.